Meeting
2020 ASCO Virtual Scientific Program
First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.
Authors
Kyriakos P. Papadopoulos
South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX
Kyriakos P. Papadopoulos , Manish Sharma , Erika Paige Hamilton , Debra L. Richardson , Graeme Hodgson , Li Zhou , Angela Volkert , Hina A. Jolin , Catherine Madigan , Michael Kelly , David A. Roth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04247126
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3662)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3662
Abstract #
TPS3662
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
First Author: Alexander I. Spira
Poster
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
First Author: Angela Tatiana Alistar
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
First Author: Ben George